Skip to main content
SpringerLink
Log in

Causes of Syncope in Patients with Alzheimer’s Disease Treated with Donepezil

  • Original Research Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Introduction

Treatment of Alzheimer’s disease (AD) with cholinesterase inhibitors carries a theoretical risk of precipitating bradycardia. Though syncope occurs in patients with AD, its aetiology is unclear. The aim of this study was to determine the causes of syncope in patients with AD who were treated with donepezil and hospitalised for evaluation of syncope.

Methods

We studied 16 consecutive patients (12 women, 4 men) with AD aged 80 ± 4 years who were hospitalised for evaluation of syncope. All patients underwent staged evaluation, ranging from physical examination to electrophysiological testing.

Results

The mean dose of donepezil administered was 7.8 mg/day, and the mean duration of donepezil treatment at the time of syncope was 12 ± 8 months. A cause of syncope was identified in 69% of patients. Carotid sinus syndrome was observed in three patients, complete atrioventricular block in two patients, sinus node dysfunction in two patients, severe orthostatic hypotension in two patients and paroxysmal atrial fibrillation in one patient. A brain tumour was discovered in one patient. No cause of syncope was found in 31% of patients despite comprehensive investigation. Repetition of the investigations after discontinuation of donepezil was noncontributory.

Conclusion

In patients with AD treated with donepezil, a noninvasive evaluation identified a probable cause of syncope in over two-thirds of patients. Cardiovascular abnormalities were predominant. Noninvasive evaluation is recommended before discontinuing treatment with cholinesterase inhibitors in patients with AD and unexplained syncope.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Fox PJ, Kohatsu N, Max W, et al. Estimating the costs of caring for people with Alzheimer disease in California: 2000–2040. J Public Health Policy 2001; 22: 88–97

    Article  PubMed  CAS  Google Scholar 

  2. Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S10–5

    PubMed  CAS  Google Scholar 

  3. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S4–9

    Article  PubMed  CAS  Google Scholar 

  4. Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001; 344: 1111–6

    Article  PubMed  CAS  Google Scholar 

  5. Grutzendler J, Morris JC. Cholinesterase inhibitors for Alzheimer’s disease. Drugs 2001; 61: 41–52

    Article  PubMed  CAS  Google Scholar 

  6. Shintani EY, Uchida KM. Donepezil: an anticholinesterase inhibitorfor Alzheimer’s disease. Am J Health Syst Pharm 1997; 54: 2805–10

    PubMed  CAS  Google Scholar 

  7. Calvo-Romero JM, Ramos-Salado JL. Symptomatic sinus bradycardia associated with donepezil [in Spanish]. Rev Neurol 1999; 28: 1070–2

    PubMed  CAS  Google Scholar 

  8. Shepherd G, Klein-Schwartz W, Edwards R. Donepezil overdose: a tenfold dosing error. Ann Pharmacother 1999; 33: 812–5

    Article  PubMed  CAS  Google Scholar 

  9. Morganroth J, Graham S, Hartman R, et al. Electrocardiographic effects of rivastigmine. J Clin Pharmacol 2002; 42: 558–68

    Article  PubMed  CAS  Google Scholar 

  10. Mant T, Troetel WM, Imbimbo BP. Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers. J Clin Pharmacol 1998; 38: 610–7

    PubMed  CAS  Google Scholar 

  11. Greenberg SM, Tennis MK, Brown LB, et al. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 2000; 57: 94–9

    Article  PubMed  CAS  Google Scholar 

  12. Bordier P, Garrigue S, Barold SS, et al. Significance of syncope in patients with Alzheimer’s disease treated with cholinesterase inhibitors. Europace 2003; 5: 429–31

    Article  PubMed  CAS  Google Scholar 

  13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th rev. ed. Washington, DC: American Psychiatric Association, 1994

    Google Scholar 

  14. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984; 34: 939–44

    Article  PubMed  CAS  Google Scholar 

  15. Kapoor WN. Current evaluation and management of syncope. Circulation 2002; 106: 1606–9

    Article  PubMed  Google Scholar 

  16. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Neurology 1996; 46: 1470

    Article  Google Scholar 

  17. Atkins D, Hanusa B, Sefcik T, et al. Syncope and orthostatic hypotension. Am J Med 1991; 91: 179–85

    Article  PubMed  CAS  Google Scholar 

  18. Bass EB, Curtiss El, Arena VC, et al. The duration of Holter monitoring in patients with syncope. Is 24 hours enough? Arch Intern Med 1990; 150: 1073–8

    Article  PubMed  CAS  Google Scholar 

  19. Brignole M, Alboni P, Benditt DG, et al. Guidelines on management (diagnosis and treatment) of syncope: update 2004. Eur Heart J 2004; 6: 467–537

    Article  Google Scholar 

  20. Almquist A, Gornick CC, Benson Jr DW, et al. Carotid sinus hypersensitivity: evaluation of the vasodepressor component. Circulation 1985; 71: 927–36

    Article  PubMed  CAS  Google Scholar 

  21. Kenny RA, Richardson DA, Steen N, et al. Carotid sinus syndrome: a modifiable risk factor for nonaccidental falls in older adults (SAFE PACE). J Am Coll Cardiol 2001; 38: 1491–6

    Article  PubMed  CAS  Google Scholar 

  22. Pavri BB, Ho RT. Syncope: identifying cardiac causes in older patients. Geriatrics 2003; 58: 26–31

    PubMed  Google Scholar 

  23. Rees SA, Curtis MJ. Tacrine inhibits ventricular fibrillation induced by ischaemia and reperfusion and widens QT interval in rat. Cardiovasc Res 1993; 27: 453–8

    Article  PubMed  CAS  Google Scholar 

  24. Savci V, Gurun MS, Cavun S, et al. Cardiovascular effects of centrally injected tetrahydroaminoacridine in conscious nor-motensive rats. Eur J Pharmacol 1998; 346: 35–41

    Article  PubMed  CAS  Google Scholar 

  25. Fitzpatrick AP, Lee RJ, Epstein LM, et al. Effect of patient characteristics on the yield of prolonged baseline head-up tilt testing and the additional yield of drug provocation. Heart 1996; 76: 406–11

    Article  PubMed  CAS  Google Scholar 

  26. McLaren AT, Allen J, Murray A, et al. Cardiovascular effects of donepezil in patients with dementia. Dement Geriatr Cogn Disord 2003; 15: 183–8

    Article  PubMed  CAS  Google Scholar 

  27. Click RL, Gersh BJ, Sugrue DD, et al. Role of invasive electrophysiologic testing in patients with symptomatic bundle branch block. Am J Cardiol 1987; 59: 817–23

    Article  PubMed  CAS  Google Scholar 

  28. Graham LA, Gray JC, Kenny RA. Comparison of provocative tests for unexplained syncope: isoprenaline and glyceryl trinitrate for diagnosing vasovagal syncope. Eur Heart J 2001; 22: 497–503

    Article  PubMed  CAS  Google Scholar 

  29. Del Rosso A, Ungar A, Bartoli P, et al. Usefulness and safety of shortened head-up tilt testing potentiated with sublingual glyceryl trinitrate in older patients with recurrent unexplained syncope. J Am Geriatr Soc 2002; 50: 1324–8

    Article  PubMed  Google Scholar 

  30. Kumar NP, Youde JH, Ruse C, et al. Responses to the prolonged head-up tilt followed by sublingual nitrate provocation in asymptomatic older adults. Age Ageing 2000; 29: 419–24

    Article  PubMed  CAS  Google Scholar 

  31. Kapoor W, Snustad D, Peterson J, et al. Syncope in the elderly. Am J Med 1986; 80: 419–28

    Article  PubMed  CAS  Google Scholar 

  32. Lipsitz LA, Wei JY, Rowe JW. Syncope in an elderly, institutionalised population: prevalence, incidence, and associated risk. Q J Med 1985; 55: 45–54

    PubMed  CAS  Google Scholar 

  33. Kenny RA. Syncope in the elderly: diagnosis, evaluation, and treatment. J Cardiovasc Electrophysiol 2003; 14: S74–7

    Article  PubMed  Google Scholar 

  34. Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N Engl J Med 2002; 347: 878–85

    Article  PubMed  Google Scholar 

  35. O’Shea D. Setting up a falls and syncope service for the elderly. Clin Geriatr Med 2002; 18: 269–78

    Article  PubMed  Google Scholar 

  36. Rubenstein LZ, Josephson KR. The epidemiology of falls and syncope. Clin Geriatr Med 2002; 18: 141–58

    Article  PubMed  Google Scholar 

  37. Kapoor WN, Karpf M, Wieand S, et al. A prospective evaluation and follow-up of patients with syncope. N Engl J Med 1983; 309: 197–204

    Article  PubMed  CAS  Google Scholar 

  38. Hu T, Huang L, Cartwright WS. Evaluation of the costs of caring for the senile demented elderly: a pilot study. Gerontologist 1986; 26: 158–63

    Article  PubMed  CAS  Google Scholar 

  39. Rice DP, Fox PJ, Max W, et al. The economic burden of Alzheimer’s disease care. Health Aff 1993; 12: 164–76

    Article  CAS  Google Scholar 

  40. Johnson N, Davis T, Bosanquet N. The epidemic of Alzheimer disease: how can we manage the costs? Pharmacoeconomics 2000; 18: 215–23

    Article  PubMed  CAS  Google Scholar 

  41. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337–42

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Cardiovascular Hospital of Haut-Leveque, avenue de Magellan, 33604, Bordeaux-Pessac cedex, France

    Philippe Bordier, Stephane Lanusse, Stephane Garrigue, Charlotte Reynard, Frederic Robert, Laurent Gencel & Alexia Lafitte

Authors
  1. Philippe Bordier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephane Lanusse
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephane Garrigue
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Charlotte Reynard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Frederic Robert
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Laurent Gencel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alexia Lafitte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philippe Bordier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bordier, P., Lanusse, S., Garrigue, S. et al. Causes of Syncope in Patients with Alzheimer’s Disease Treated with Donepezil. Drugs Aging 22, 687–694 (2005). https://doi.org/10.2165/00002512-200522080-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200522080-00005

Keywords

Search

Navigation